Drug Trial Radar · NCT00709527
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Oct 16, 2008
Primary completion
Dec 30, 2009
Study completion Dec 30, 2009
Sponsor
- Lead sponsor
- Ophthotech CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of multiple doses of ARC1905 intravitreous injection when administered in combination with multiple doses of Lucentis® 0.5 mg/eye, or with one induction dose of Lucentis 0.5 mg/eye in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Conditions
- Neovascular Age-Related Macular Degeneration
Interventions
Avacincaptad PegolDrug
intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of any dose-limiting toxicity (DLT), safety endpoints include adverse events, vital signs, ophthalmic variables and outcomesTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ophthotech Corp
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.